A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Study acronym: FORAGER-2
StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites reduced: 284 → 276 locations
  2. Trial sites reduced: 290 → 284 locations
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 1 of 11 entries
  3. Study sites: 289 to 290v22
  4. Trial sites expanded: 286 → 289 locationsv21
  5. Study sites: 287 to 286v20
  6. Trial sites expanded: 284 → 287 locationsv19
  7. Site details revised at 1 of 284 sitesv18
  8. Study sites revised (284)v17
  9. Study sites: 282 to 284v16
  10. Study sites: 281 to 282v15
  11. Study sites: 279 to 281v14
  12. Site details revised at 16 of 279 sitesv13
  13. Study sites: 278 to 279v12
  14. Study sites: 276 to 278v11
  15. Study sites: 273 to 276v10
  16. Site contacts updated at 1 of 273 sitesv9
  17. Study sites: 271 to 273v8
  18. Site details revised at 8 of 271 sitesv7
  19. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 268 to 271
    • Start date changed from estimate of Nov 2025 to Dec 12, 2025
    v6
  20. Study sites: 265 to 268v5
  21. Site details revised at 1 of 265 sitesv4
  22. Re-verified, no change to tracked fieldsv3
  23. Study sites: 254 to 265v2
  24. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Bladder Cancer
1,058 trials monitored
See 76 trials at risk
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
Trial Details
NCT Number NCT07218380
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Related terms Carcinoma, Transitional Cell, Neoplasm Metastasis, Urinary Bladder Neoplasms
Enrollment 450 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov